中国麻风皮肤病杂志 ›› 2017, Vol. 33 ›› Issue (10): 596-598.

• 论著 • 上一篇    下一篇

重组人II型肿瘤坏死因子受体-抗体融合蛋白治疗疱疹样脓疱病一例并文献复习

储小燕  芦桂青  毕志刚   

  1. 南京医科大学附属南京明基医院，江苏南京，210019
  • 出版日期:2017-10-15 发布日期:2018-12-10
  • 通讯作者: 毕志刚，E-mail: eltonbi@21cn.com

Recombinant human tumor necrosis factor-α receptor II:IgG Fc fusion protein for the treatment of impetigo herpetiformis: a case report and literature review

CHU Xiaoyan, LU Guiqing, BI Zhigang.   

  1. The Affiliated BenQ Hospital of Nanjing Medical University , Nanjing 210019, China
  • Online:2017-10-15 Published:2018-12-10
  • Contact: BI Zhigang, E-mail: eltonbi@21cn.com

PDF (PC)

114

摘要： 患者，女，26岁。全身泛发性红斑、脓疱2个月，加重伴高热1周。银屑病病史13年，妊娠28周。外周血白细胞及中性粒细胞偏高，血及脓疱细菌培养阴性，根据临床表现及辅助检查可诊断为疱疹样脓疱病。入院后给予人免疫球蛋白20 mg,头孢曲松1.0 g,1次/日，治疗2周效果不佳，加用重组人II型肿瘤坏死因子受体-抗体融合蛋白25 mg,2次/周，2周后好转出院，新生儿健康。

关键词: 疱疹样脓疱病, 重组人II型肿瘤坏死因子受体-抗体融合蛋白

Abstract: A 26-year-old female presented with widespread erythema and superficial sterile pustules for 2 months and aggravated for 1 week. The patient had a psoriatic history for 13 years and she was at 28 week of pregnancy. Laboratory examination revealed hypoalbuminemia, leukocytosis and neutrophilia. Blood and pus were culture-negative for bacilli. The diagnosis of impetigo herpetiformis was made according to the clinical manifestations and laboratory parameters. The patient was treated with human immunoglobulin 20mg and ceftriaxone 1.0 g, once a day for 2 weeks with poor improvement and the recombinant human tumor necrosis factor-α receptor II:IgG Fc fusion protein was used additionally, 25 mg, twice a week for 2 weeks. The treatment was effective and a healthy baby was delivered.

Key words: impetigo herpetiformis, recombinant human tumor necrosis factor-α receptor II:IgG Fc fusion protein